Endothelial dysfunction in subjects with subclinical hyperthyroidism

Journal of Endocrinological Investigation

Volumn 29, Issue 3, 2006, Pages 197-200

  Coban, E ^a   Aydemir, M ^a   Yazicioglu, G ^a   Ozdogan, M ^a  

^a AKDENIZ UNIVERSITY FACULTY OF MEDICINE   (Turkey)

Author keywords

Cardiovascular risk; Endothelial dysfunction; Subclinic hyperthyroidism; von Willebrand factor

Indexed keywords

ALANINE AMINOTRANSFERASE; CHOLESTEROL; CREATININE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIOTHYRONINE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; THYROTROPIN; THYROXINE; TRIACYLGLYCEROL; VON WILLEBRAND FACTOR;

ADULT; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CONTROLLED STUDY; ENDOTHELIUM LESION; EUTHYROIDISM; FEMALE; FREE LIOTHYRONINE INDEX; FREE THYROXINE INDEX; GRAVES DISEASE; HUMAN; HYPERTHYROIDISM; LIOTHYRONINE BLOOD LEVEL; MALE; THYROXINE BLOOD LEVEL;

EID: 33646265772     PISSN: 03914097     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03345539     Document Type: Article

References (29)

1. Zoghi M, Nalbantgil I. Hypertension and endothelial dysfunction. Anadolu Kardiyol Derg 2002, 2: 142-7.
2. Poredos P. Endothelial dysfunction in the pathogenesis of atherosclerosis. Int Angiol 2002, 21: 109-16.
3. Lip GY, Blann AD. Von Willebrand factor: a marker of endothelial dysfunction in vascular disorders? Cardiovasc Res 1997, 34: 255-65.
4. Wagner DD. Cell biology of von Willebrand factor. Annu Rev Cell Biol 1990, 6: 217-46.
5. Pearson JD. Markers of endothelial cell perturbation and damage. Br J Rheumatol 1993, 32: 651-2.
6. Blann AD, Taberner DA. A reliable marker of endothelial cell dysfunction: does it exist? Br J Haematol 1995, 90: 244-8.
7. Biondi B, Palmieri EA, Klain M, Schlumberger M, Filetti S, Lombardi G. Subclinical hyperthyroidism: clinical features and treatment options. Eur J Endocrinol 2005, 152: 1-9.
8. Canaris GJ, Manovitz NR, Mayor G, Ridgway EC. The Colorado thyroid disease prevalence study. Arch Intern Med 2000, 160: 526-34.
9. Marqusee E, Haden ST, Utiger RD. Subclinical thyrotoxicosis. Endocrinol Metab Clin North Am 1998, 27: 37-49.
10. Wang C, Crapo LM. The epidemiology of thyroid diseases and implications for screening. Endocrinol Metab Clin North Am 1977, 26: 189-218.
11. Samuels MH. Subclinical thyroid disease in the elderly. Thyroid 1998, 8: 803-13.
12. Biondi B, Palmieri EA, Lombardi G, Fazio S. Effects of subclinical thyroid dysfunction on the heart. Ann Intern Med 2002, 137: 904-14.
13. Tenerz A, Forberg R, Jansson R. Is a more active attitude warranted in patients with subclinical thyrotoxicosis? J Intern Med 1990, 228: 229-33.
14. Sawin CT, Geller A, Wolf PA, et al. Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons. N Engl J Med 1994, 331: 1249-52.
15. Auer J, Scheibner P, Mische T, Langsteger W, Eber O, Eber B. Subclinical hyperthyroidism as a risk factor for atrial fibrillation. Am Heart J 2001, 142: 838-42.
16. Biondi B, Palmieri EA, Lombardi G, Fazio S. Effects of subclinical thyroid dysfunction on the heart. Ann Intern Med. 2002, 137: 904-14.
17. Sgarbi JA, Villaca F, Garbeline B, Villar HE, Romaldini JH. The effects of early antithyroid therapy for endogenous subclinical hyperthyroidism in clinical and heart abnormalities. J Clin Endocrinol Metab 2003, 88: 1672-7.
18. Biondi B, Fazio S, Palmieri EA, et al. Effects of chronic subclinical hyperthyroidism on cardiac morphology and function. Cardiologia 1999, 44: 443-9.
19. Petretta M, Bonaduce D, Spinelli L, et al. Cardiovascular haemodynamics and cardiac autonomic control in patients with subclinical and overt hyperthyroidism. Eur J Endocrinol 2001, 145: 691-6.
20. Parle JV, Maisonneuve P, Sheppard MC, Boyle P, Franklyn JA. Prediction of all-cause and cardiovascular mortality in elderly people from one low serum thyrotropin result: a 10-year cohort study. Lancet 2001, 358: 861-5.
21. Biondi B, Palmieri EA, Filetti S, Lombardi G, Fazio S. Mortality in elderly patients with subclinical hyperthyroidism. Lancet 2002, 359: 799-800.
22. Myrup B, Bregengard C, Faber J. Primary haemostasis in thyroid disease. J Intern Med. 1995, 238: 59-63.
23. Erem C, Ersoz HO, Karti SS, et al. Blood coagulation and fibrinolysis in patients with hyperthyroidism. J Endocrinol Invest 2002, 25: 345-50.
24. Burggraaf J, Lalezari S, Emeis JJ, et al. Endothelial function in patients with hyperthyroidism before and after treatment with propranolol and thiamazol. Thyroid 2001, 11: 153-60.
25. Rosc D, Drewniak W, Zastawna E, Paczuski R, Graczykowska A. Markers of endothelial stimulation in hyperthyroidism. Pol Merkuriusz Lek 1999, 6: 79-81.
26. Liu L, Wang X, Lin Z, Wu H. Elevated plasma levels of VWF: Ag in hyperthyroidism are mediated through beta-adrenergic receptors. Endocr Res 1993, 19: 123-33.
27. Friedewald WT, Levi RI, Fredricksen DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972, 18: 499-502.
28. Blann AD, McCollum CN. Von Willebrand factor, endothelial cell damage and atherosclerosis. Eur J Vasc Surg 1994, 8: 10-5.
29. Cikim AS, Oflaz H, Ozbey N, et al. Evaluation of endothelial function in subclinical hypothyroidism and subclinical hyperthyroidism. Thyroid 2004, 14: 605-9.